Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and leukemia group B study 9431

Journal of Clinical Oncology

Volumn 20, Issue 20, 2002, Pages 4191-4198

  Vokes, Everett E ^a   Herndon II, James E ^a   Crawford, Jeffrey ^a   Leopold, Kenneth A ^a   Perry, Michael C ^a   Miller, Antonius A ^a   Green, Mark R ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGITIS; GRANULOCYTOPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 0037108701     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.03.054     Document Type: Article

References (38)

1. Ginsberg R, Vokes EE, Rosenzweig K: Non-small cell lung cancer, in DeVita JV, Hellman S, Rosenberg SA (eds): Cancer-Principles and Practice of Oncology (ed 6). Philadelphia, PA, JB Lippinoctt Co, 2001, pp 925-982
2. Bunn PA Jr, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 4:1087-1100, 1998
3. Hoffman PC, Mauer AM, Vokes EE: Lung cancer. Lancet 355:479-485, 2000 (published erratum appears in Lancet 355:1280, 2000)
4. Johnson DH: Treatment strategies for metastatic non-small-cell lung cancer. Clin Lung Cancer 1:34-41, 1999
5. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
6. Bonomi P, Kim K, Fairclough D, et al: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623-631, 2000
7. Giaccone G, Splinter TA, Debruyne C, et al: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer: The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16:2133-2141, 1998
8. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
9. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16:2459-2465, 1998
10. Sandler AB, Nemunaitis J, Denham C, et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130, 2000
11. Vokes EE, Bitran JD: Non-small-cell lung cancer: Toward the next plateau. Chest 106:659-661, 1994 (editorial)
12. Shepherd FA: Chemotherapy for non-small cell lung cancer: Have we reached a new plateau? Semin Oncol 26:3-11, 1999
13. Gordon GS, Vokes EE: Chemoradiation for locally advanced, unresectable NSCLC: New standard of care, emerging strategies. Oncology (Huntingt) 13:1075-1088; discussion, 1088, 1091-1094, 1999
14. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996
15. Vokes EE, Green MR: Clinical studies in non-small cell lung cancer: The CALGB experience. Cancer Invest 16:72-79, 1998
16. Sause W, Kolesar P, Taylor SI, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358-364, 2000
17. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991
18. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992
19. Jeremic B, Shibamoto Y, Acimovic L, et al: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458, 1995
20. Albain KS, Rusch VW, Crowley JJ, et al: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880-1892, 1995
21. Albain K, Crowley JJ, Turrisi AT, et al: Concurrent cisplatin/etoposide plus radiotherapy (PE+RT) for pathologic stage (pathTN) IIIB non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) phase II study (S9019). Proc Am Soc Clin Oncol 16:128a, 1997 (abstr 450)
22. Gaspar L, Gandara D, Chansky K, et al: Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIb nonsmall cell lung cancer (NSCLC) (SWOG 9504): Patterns of failure and updated survival. Proc Am Soc Clin Oncol 20:315a, 2001 (abstr 1255)
23. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
24. Curran W, Scott C, Langer C: Phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: Report of Radiation Therapy Oncology Group 9410, 9th World Conference on Lung Cancer. Lung Cancer 29:93, 2000
25. Edelstein MP, Wolfe LA 3rd, Duch DS: Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. Semin Oncol 23:41-47, 1996
26. Choy H, Rodriguez FF, Koester S, et al: Investigation of Taxol as a potential radiation sensitizer. Cancer 71:3774-3778, 1993
27. Milas L, Hunter NR, Mason KA, et al: Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 54:3506-3510, 1994
28. Shewach DS, Hahn TM, Chang E, et al: Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54:3218-3223, 1994
29. Lawrence TS, Chang EY, Hahn TM, et al: Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34:867-872, 1996
30. Meyer J, Spencer SA, Jennelle RLS, et al: Phase I study of concurrent Taxol/cisplatin with thoracic radiation (TR) in locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 15:372, 1996 (abstr)
31. Masters GA, Haraf DJ, Hoffman PC, et al: Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol 16:2157-2163, 1998
32. Vokes EE, Gregor A, Turrisi AT: Gemcitabine and radiation therapy for non-small cell lung cancer. Semin Oncol 25:66-69, 1998
33. Vokes E, Leopold KA, Herndon JE, et al: A CALGB randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Inc CT) and concomitant chemoradiotherapy (XRT) in stage IIIB non-small cell lung cancer (NSCLC): Feasibility data (CALGB study). Proc Am Soc Clin Oncol 16:455a, 1997 (abstr 1636)
34. Clamon G, Herndon J, Cooper R, et al: Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17:4-11, 1999
35. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
36. Pierre F, Maurice P, Gilles R, et al: A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC) (GLOT-GFPC NPC 95-01 study). Proc Am Soc Clin Oncol 20:312a, 2001 (abstr 1246)
37. Zatloukal PV, Petruzelka L, Zemanova M, et al: Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (v-p) in locally advanced non-small cell lung cancer: A randomized phase II study. Proc Am Soc Clin Oncol 21:290a, 2002 (abstr 1159)
38. Socinski MA, Rosenman JG, Schell MJ, et al: Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: A modified phase I trial. Cancer 89:534-542, 2000